Celldex Therapeutics Inc 's Cash & cash equivalent grew by 58.95 % in the Q2 2026 sequentially, faster than Current Liabilities, this led to improvement in Celldex Therapeutics Inc 's Quick Ratio to 11.7, Quick Ratio remained below Celldex Therapeutics inc average.

Within In Vitro & In Vivo Diagnostic Substances industry Celldex Therapeutics inc booked the highest Quick Ratio than Celldex Therapeutics Inc in the second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 534, from total ranking in the first quarter 2026 at 554.

Explain Quick Ratio?
How much Cash & cash equivalents CLDX�s has?
What are CLDX�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

CLDX Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	86.04 %	60.76 %	29.09 %	44.78 %	19.18 %
Y / Y Cash & cash equivalent Change	13.84 %	-32.95 %	-28.5 %	-22.85 %	-21.44 %
Quick Ratio MRQ	11.7	8.77	10.17	12.55	19.12
CLDX's Total Ranking	# 534	# 554	# 427	# 270	# 249
Seq. Current Liabilities Change	19.14 %	0.94 %	9.74 %	40.96 %	2.95 %
Seq. Cash & cash equivalent Change	58.95 %	-12.94 %	-11.08 %	-7.47 %	-6.38 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 1
Healthcare Sector	# 135
Overall Market	# 399

Quick Ratio Statistics
High	Average	Low
31.34	12.34	3.15
(Mar 31 2024)		(Dec 31 2010)

Financial Statements
Celldex Therapeutics Inc 's Current Liabilities	$ 61 Millions	Visit CLDX's Balance sheet
Celldex Therapeutics Inc 's Cash & cash equivalent	$ 718 Millions	Visit CLDX's Balance sheet
Source of CLDX's Sales		Visit CLDX's Sales by Geography

Cumulative Celldex Therapeutics Inc 's Quick Ratio

CLDX's Quick Ratio for the trailling 12 Months

CLDX Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	53.95 %	38.56 %	29.39 %	28.83 %	20.96 %
Y / Y Cash & cash equivalent TTM Growth	-18.46 %	-26.15 %	-22.59 %	-6.9 %	21.87 %
Quick Ratio TTM	10.8	12	14.81	17.3	20.39
Total Ranking TTM	# 1668	# 2003	# 1439	# 1369	# 1202
Seq. Current Liabilities TTM Growth	15.59 %	11.98 %	7.61 %	10.52 %	4.04 %
Seq. Cash & cash equivalent TTM Growth	4 %	-9.22 %	-7.91 %	-6.2 %	-5.82 %

Quick ratio ranking by company, industry and sector >> Back to CLDX Financial Strength Comparisons >> Go to Compare CLDX Quick Ratio to its Competitors

On the trailing twelve months basis Due to increase in Current Liabilities in the Q2 2026 to $61.32 millions, cumulative Quick Ratio decreased to 10.8 above the CLDX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Celldex Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3235.

Explain Quick Ratio?
How much Cash & cash equivalents CLDX�s has?
What are CLDX�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 15
Healthcare Sector	# 900
Within the Market	# 534

trailing twelve months Quick Ratio Statistics
High	Average	Low
4.2	2.14	0.65
(Dec 31 2013)		(Dec 31 2025)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Celldex Therapeutics inc	11.70	$ 717.587 Millions	$ 61.325 Millions
Intellia Therapeutics Inc	5.51	$ 437.759 Millions	$ 79.392 Millions
Qc Technologies Inc	3.00	$ 10.987 Millions	$ 3.669 Millions
Alpha Teknova Inc	2.54	$ 17.436 Millions	$ 6.872 Millions

Date modified: 2026-09-08T15:11:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.